Vnitr Lek 2012, 58(7-8):175-180

High dose treatments and preparatory regimens prior to haematopoietic stem cell transplantation

M. Tomíška
Interní hematologická a onkologická klinika Lékařské fakulty MU a FN Brno, pracoviště Bohunice, přednosta prof. MUDr. Jiří Mayer, CSc.

High-dose chemotherapy can be defined as utilization of cytotoxic drug doses that produce bone marrow ablation. Transfusion of autologous graft serves as rescue from otherwise fatal myelotoxicity. Immune reaction of graft versus tumor that lowers relaps rates of malignant disease becomes an important contribution of allogeneic hematopoietic stem cell transplantation. New reduced intensity conditioning regimens with lower initial cytotoxicity rely on this immune effect with the potencial of additional elimination of remaining cancer cells. Decreased toxicity of these regimens enables treatment of patients with comorbidity and/or in higher age.

Keywords: high-dose chemotherapy; hematopoietic stem cell transplantation; conditioning regimen; nonmyeloablative conditioning

Received: March 28, 2012; Published: July 1, 2012  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Tomíška M. High dose treatments and preparatory regimens prior to haematopoietic stem cell transplantation. Vnitr Lek. 2012;58(7-8):175-180.
Download citation

References

  1. Doroshow JH, Synold TW. Pharmacologic basis for high-dose chemotherapy. In: Thomas' Hematopoietic Cell Transplantation. Singapore: Blackwell Publishing 2008: 289-315. Go to original source...
  2. Bensinger WI. High-dose preparatory regimens. In: Thomas' Hematopoietic Cell Transplantation. Singapore: Blackwell Publishing 2008: 316-330. Go to original source...
  3. Soiffer RJ, LeRademacher J, Ho V et al. Impact of immune modulation with anti-T-cell antibodies on the outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for hematologic malignancies. Blood 2011; 117: 6963-6970. Go to original source... Go to PubMed...
  4. Uberti JP, Agovi MA, Tarima S et al. Comparative analysis of BU and CY versus CY and TBI in full intensity unrelated marrow donor transplantation for AML, CML and myelodysplasia. Bone Marrow Transplant 2011; 46: 34-43. Go to original source... Go to PubMed...
  5. Cantoni N, Gerull S, Heim D et al. Order of application and liver toxicity in patients given BU and CY containing conditioning regimens for allogeneic hematopoietic SCT. Bone Marrow Transplant 2011; 46: 344-349. Go to original source... Go to PubMed...
  6. Hill-Kayser CE, Plastaras JP, Tochner Z et al. TBI during BM and SCT: review of the past, discussion of the present and consideration of future directions. Bone Marrow Transplant 2011; 46: 475-484. Go to original source... Go to PubMed...
  7. Mickelson DM, Sproat L, Dean R et al. Comparison of donor chimerism following myeloablative and nonmyeloablative allogeneic hematopoietic SCT. Bone Marrow Transplant 2011; 46: 84-89. Go to original source... Go to PubMed...
  8. Khabori MA, El-Emary M, Xu W et al. Impact of intensity of conditioning therapy in patients aged 40-60 years with AML/myelodysplastic syndrome undergoing allogeneic transplantation. Bone Marrow Transplant 2011; 46: 516-522. Go to original source... Go to PubMed...
  9. Kline J, Subbiah S, Lazarus HM et al. Autologous graft-versus-host disease: harnessing anti-tumor immunity through impaired self-tolerance. Bone Marrow Transplant 2008; 41: 505-513. Go to original source... Go to PubMed...
  10. Wallen H, Gooley TA, Deeg HJ et al. Ablative allogeneic hematopoietic cell transplantation in adults 60 years of age and older. J Clin Oncol 2005; 23: 3439-3446. Go to original source... Go to PubMed...
  11. Gyurkocza B, Storb R, Storer BE et al. Nonmyeloablative allogeneic hematopoietic cell transplantation in patients with acute leukemia. J Clin Oncol 2010; 28: 2859-2867. Go to original source... Go to PubMed...
  12. Cetkovský P. Alogenní transplantace kmenových buněk krvetvorby po přípravě s redukovanou intenzitou. Bilancování poznatků po deseti letech používání této metody. Postgraduální medicína 2007; 9: 336-343.
  13. Schleuning M, Günther W, Tischer J et al. Dose-dependent effects of in vivo antithymocyte globulin during conditioning for allogeneic bone marrow transplantation from unrelated donors in patients with chronic phase CML. Bone Marrow Transplant 2003; 32: 243-250. Go to original source... Go to PubMed...
  14. Andersson BS, de Lima M, Thall PF et al. Once daily i.v. busulfan and fludarabine (i.v. Bu-Flu) compares favourably with i.v. busulfan and cyclophosphamide (i.v.BuCy2) as pretransplant conditioning therapy in AML/MDS. Biol Blood Marrow Transplant 2008; 14: 672-684. Go to original source... Go to PubMed...




Vnitřní lékařství

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.